Cantor Fitzgerald Upgrades Zealand Pharma A/S (OTCMKTS:ZLDPF) to “Strong-Buy”

Zealand Pharma A/S (OTCMKTS:ZLDPF) was upgraded by investment analysts at Cantor Fitzgerald to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Separately, JPMorgan Chase & Co. began coverage on shares of Zealand Pharma A/S in a report on Friday, November 8th. They issued an “overweight” rating on the stock.

Zealand Pharma A/S Price Performance

Shares of OTCMKTS ZLDPF opened at $102.98 on Tuesday. Zealand Pharma A/S has a fifty-two week low of $65.26 and a fifty-two week high of $141.74. The stock has a market capitalization of $7.31 billion, a price-to-earnings ratio of -42.38 and a beta of 0.89. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The business has a 50-day moving average of $102.26 and a 200-day moving average of $117.80.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.